Walleye Capital
SPRB

Walleye Capital’s Spruce Biosciences SPRB Stock Holding History

Walleye Capital’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,386
Closed -$141K – 6099
2024
Q1 		$141K Buy
+2,386
New +$607K ﹤0.01% 4192

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Walleye Capital's SPRB Position: Q2 2024 in Review

Walleye Capital sold out of Spruce Biosciences (SPRB) in Q2 2024, closing a stake of 2,386 shares — an estimated $141K sold.

Walleye Capital first reported a position in SPRB in Q1 2024 and held it in 1 quarter. The position peaked at $141K in Q1 2024. 37 funds tracked by Wall St. Rank hold SPRB as of Q2 2024.

  • Walleye Capital reported no remaining Spruce Biosciences position as of Q2 2024 after selling out during the quarter.
  • Walleye Capital sold 2,386 Spruce Biosciences shares in Q2 2024, an estimated $141K.
  • Walleye Capital first reported a position in Spruce Biosciences in Q1 2024 and held it in 1 quarter.
  • Walleye Capital's Spruce Biosciences position peaked at $141K in Q1 2024.
  • 37 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.